Genprex, Inc. (GNPX) 10-K Summary
Business Context and Reporting Period
Company: Genprex, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Genprex is a clinical-stage gene therapy company developing therapies for oncology and diabetes. Its lead oncology candidate, REQORSA (quaratusugene ozeplasmid), utilizes a non-viral delivery system to express the TUSC2 tumor suppressor gene. The diabetes candidate, GPX-002, aims to transform alpha cells into insulin-producing beta-like cells. The company operates as a single segment and is currently focused on advancing clinical trials while managing significant liquidity constraints.
Key Financial Metrics
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(16.23) million | $(21.11) million |
| Operating Expenses | $15.52 million | $21.17 million |
| Cash and Cash Equivalents (Year-End) | $7.83 million | $1.60 million |
| Accumulated Deficit | $(171.03) million | $(154.80) million |
| Net Cash Used in Operating Activities | $(15.31) million | $(17.92) million |
| Net Cash Provided by Financing Activities | $21.54 million | $12.01 million |
Note: The company has no debt obligations as of December 31, 2025.
Material Changes vs. Prior Period
- Expense Reduction: Net loss decreased by 23% ($4.88 million) primarily due to aggressive cost-cutting measures, including a reduction in headcount from 15 to 13 employees and the closure of the Acclaim-2 clinical trial.
- Research & Development (R&D): R&D expenses decreased by 11% ($1.11 million) to $9.43 million, driven by the cessation of the Acclaim-2 trial and reduced clinical manufacturing costs.
- General & Administrative (G&A): G&A expenses decreased significantly by 43% ($4.55 million) to $6.09 million. This reduction was attributed to the absence of one-time charges related to executive separation and accounting policy adjustments that occurred in 2024, as well as reduced share-based compensation and professional service fees.
- Capital Raising: Financing activities increased substantially. In 2025, the company raised approximately $21.5 million through ATM offerings, an Equity Line of Credit (ELOC), and registered direct offerings, compared to $12.0 million in 2024.
- Stock Structure: The company effected a 1-for-50 reverse stock split on October 21, 2025, to regain compliance with Nasdaq listing requirements.
Guidance, Outlook, and Risks
Clinical Outlook:
- Acclaim-1 (NSCLC): Currently enrolling in the Phase 2a expansion. Interim analysis expected in the second half of 2026.
- Acclaim-3 (SCLC): Currently enrolling in the Phase 2 expansion. Interim analysis expected in the second half of 2026.
- Acclaim-2 (NSCLC): Enrollment ceased in August 2024 due to slow recruitment; no patients currently receiving treatment.
- Diabetes (GPX-002): Preclinical stage. The company met with the FDA in February 2026 regarding IND-enabling studies. A wholly-owned subsidiary, Convergen Biotech, Inc., was formed to potentially separate the diabetes program.
Liquidity and Going Concern:
- The company has raised substantial doubt regarding its ability to continue as a going concern due to recurring losses and an accumulated deficit of $171 million.
- Management estimates current cash resources (including subsequent proceeds of $13.3 million raised in early 2026) will fund operations into the second quarter of 2027.
- Additional capital will be required to complete clinical trials and commercialization efforts. Failure to secure funding could force the company to curtail or cease operations.
Key Risks:
- Capital Availability: Dependence on equity markets and ATM facilities for survival; potential dilution to shareholders.
- Clinical Trial Success: High risk of failure in clinical development; enrollment challenges have already impacted the Acclaim-2 trial.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting due to a lack of segregation of duties and insufficient accounting personnel depth.
- Regulatory Compliance: Subject to mandatory monitoring by Nasdaq for one year following the 2025 reverse split to ensure continued compliance with stockholders' equity rules.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $13.3 million raised in early 2026 combined with year-end cash to sustain operations through Q2 2027 as projected.
- Internal Controls: Review the status of remediation efforts for the material weaknesses in internal controls over financial reporting disclosed in Item 9A.
- Enrollment Rates: Monitor patient enrollment progress in the Acclaim-1 and Acclaim-3 trials to ensure interim analysis timelines for 2026 are met.
- Capital Structure: Assess the impact of the 1-for-50 reverse stock split on liquidity and trading volume.
- Subsidiary Strategy: Track the progress of the potential separation of the diabetes program into Convergen Biotech, Inc.